Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Net Income (2019 - 2025)

Cyclerion Therapeutics has reported Net Income over the past 6 years, most recently at -$1.0 million for Q3 2025.

  • Quarterly results put Net Income at -$1.0 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was -$4.1 million (changed N/A YoY), and the annual figure for FY2023 was $7.3 million, up 128.38%.
  • Net Income for Q3 2025 was -$1.0 million at Cyclerion Therapeutics, up from -$1.7 million in the prior quarter.
  • Over the last five years, Net Income for CYCN hit a ceiling of $13.5 million in Q3 2023 and a floor of -$16.2 million in Q2 2021.
  • Median Net Income over the past 4 years was -$4.9 million (2022), compared with a mean of -$6.2 million.
  • Biggest five-year swings in Net Income: grew 3.07% in 2022 and later soared 321.28% in 2023.
  • Cyclerion Therapeutics' Net Income stood at -$14.3 million in 2021, then skyrocketed by 79.82% to -$2.9 million in 2022, then soared by 565.74% to $13.5 million in 2023, then tumbled by 107.47% to -$1.0 million in 2025.
  • The last three reported values for Net Income were -$1.0 million (Q3 2025), -$1.7 million (Q2 2025), and -$1.5 million (Q1 2025) per Business Quant data.